Trial · NCT04804605
Results by group74
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 74
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With ≥1 Treatment-emergent Adverse Event (TEAE) | ARQ-151-311/312: RC/RC 0.15% Group | 151 | Participants | ||
| Number of Participants With ≥1 Treatment-emergent Adverse Event (TEAE) | ARQ-151-311/312: VC/RC 0.15% Group | 90 | Participants | ||
| Number of Participants With ≥1 Treatment-emergent Adverse Event (TEAE) | ARQ-151-315: RC/RC 0.05% or 0.15% Group | 189 | Participants | ||
| Number of Participants With ≥1 Treatment-emergent Adverse Event (TEAE) | ARQ-151-315: VC/RC 0.05% or 0.15% Group | 91 | Participants | ||
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-311/312: RC/RC 0.15% Group | Week 4 | 40.1 | 95% Confidence Interval 35.61 to 44.83 | percentage of participants |
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-311/312: VC/RC 0.15% Group | Week 4 | 35.7 | 95% Confidence Interval 29.60 to 42.36 | percentage of participants |
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-315: RC/RC 0.05% or 0.15% Group | Week 4 | 37.7 | 95% Confidence Interval 32.98 to 42.77 | percentage of participants |
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-315: VC/RC 0.05% or 0.15% Group | Week 4 | 40.8 | 95% Confidence Interval 33.88 to 48.20 | percentage of participants |
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-311/312: RC/RC 0.15% Group | Week 12 | 42.2 | 95% Confidence Interval 37.42 to 47.08 | percentage of participants |
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-311/312: VC/RC 0.15% Group | Week 12 | 36.9 | 95% Confidence Interval 30.55 to 43.68 | percentage of participants |
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-315: RC/RC 0.05% or 0.15% Group | Week 12 | 40.0 | 95% Confidence Interval 35.10 to 45.07 | percentage of participants |
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-315: VC/RC 0.05% or 0.15% Group | Week 12 | 53.0 | 95% Confidence Interval 45.62 to 60.25 | percentage of participants |
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-311/312: RC/RC 0.15% Group | Week 24 | 48.2 | 95% Confidence Interval 43.25 to 53.18 | percentage of participants |
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-311/312: VC/RC 0.15% Group | Week 24 | 46.3 | 95% Confidence Interval 39.27 to 53.48 | percentage of participants |
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-315: RC/RC 0.05% or 0.15% Group | Week 24 | 46.4 | 95% Confidence Interval 41.25 to 51.54 | percentage of participants |
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-315: VC/RC 0.05% or 0.15% Group | Week 24 | 54.3 | 95% Confidence Interval 46.72 to 61.75 | percentage of participants |
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-311/312: RC/RC 0.15% Group | Week 36 | 45.5 | 95% Confidence Interval 38.75 to 52.33 | percentage of participants |
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-311/312: VC/RC 0.15% Group | Week 36 | 49.6 | 95% Confidence Interval 39.36 to 59.82 | percentage of participants |
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-315: RC/RC 0.05% or 0.15% Group | Week 36 | 42.5 | 95% Confidence Interval 37.31 to 47.82 | percentage of participants |
| Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Score of 0 or 1 at Each Assessment | ARQ-151-315: VC/RC 0.05% or 0.15% Group | Week 36 | 47.6 | 95% Confidence Interval 39.94 to 55.45 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04804605/results